• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia.
【24h】

Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia.

机译：Muraglitazar：一种用于治疗2型糖尿病和相关血脂异常的药物。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Many studies indicate that postprandial metabolic abnormalities, such as hyperglycemia and dyslipidemia, which are exaggerated and prolonged in type 2 diabetes, are important risk factors for cardiovascular disease. Different pharmacotherapies have been developed to specifically target these risk factors associated with type 2 diabetes. The peroxisome proliferator-activated receptor (PPAR) agonists, which are potent insulin sensitizers, have been the focus of much research during the past decade. Since their development, PPAR agonists have emerged as an important target for the treatment of insulin resistance and dyslipidemia. The more recent development of agonists that selectively target both the alpha and gamma PPARs has provided a potential treatment of global risk in patients with the metabolic syndrome or type 2 diabetes. Muraglitazar is a non-thiazolidinedione, oxybenzylglycine dual PPARalpha/gamma agonist that is in advanced clinical development for the treatment of type 2 diabetes and its associated dyslipidemia. This article summarizes the available clinical data on the efficacy and safety of muraglitazar in patients with type 2 diabetes.
机译：许多研究表明，餐后代谢异常（例如高血糖和血脂异常）在2型糖尿病中被夸大和延长，是心血管疾病的重要危险因素。已经开发出不同的药物疗法来专门针对与2型糖尿病相关的这些危险因素。过氧化物酶体增殖物激活受体（PPAR）激动剂是有效的胰岛素增敏剂，在过去十年中一直是许多研究的重点。自其发展以来，PPAR激动剂已成为治疗胰岛素抵抗和血脂异常的重要靶标。选择性靶向α和PPARs的激动剂的最新发展为代谢综合征或2型糖尿病患者的整体风险提供了潜在的治疗方法。 Muraglitazar是一种非噻唑烷二酮，氧苄基甘氨酸双重PPARalpha /γ激动剂，目前正在用于治疗2型糖尿病及其相关血脂异常的先进临床研究中。本文总结了关于穆拉格他沙治疗2型糖尿病患者的有效性和安全性的可用临床数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号